Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 563 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PCI Clear all
Active, not recruiting Not applicable Interventional

Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE)

NCT06181240
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Calcification
Interventions
Intravascular lithotripsy
Device
Lead sponsor
Bolt Medical
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
31
States / cities
La Jolla, California • Los Angeles, California • Riverside, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 2Phase 3 Interventional

TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent

NCT00292474
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
percutaneous coronary intervention
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2008 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 4 Interventional Results available

Colchicine in Percutaneous Coronary Intervention

NCT02594111
View directory record Official record
Conditions
Coronary Artery Disease, Acute Coronary Syndrome
Interventions
Colchicine vs Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Not applicable Interventional

Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

NCT00413309
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Video Capsule Endoscopy
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2009 · Synced Oct 23, 2026, 1:34 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

NCT04547140
View directory record Official record
Conditions
COVID-19
Interventions
Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment
Biological · Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 3 Interventional

Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)

NCT00043940
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia, Thrombosis
Interventions
bivalirudin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Oct 23, 2026, 1:34 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI

NCT00546260
View directory record Official record
Conditions
Myocardial Infarction
Interventions
placebo, PRT060128 Potassium
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Tallahassee, Florida • Des Moines, Iowa • Lexington, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 23, 2026, 1:34 AM EDT
Recruiting No phase listed Observational

IVUS CHIP UPP Registry

NCT06625801
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Disease Risk High, Complex Coronary Artery Disease
Interventions
IVUS
Device
Lead sponsor
ECRI bv
Industry
Eligibility
18 Years and older
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Loma Linda, California • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00003812
View directory record Official record
Conditions
Lung Cancer
Interventions
filgrastim, carboplatin, etoposide, paclitaxel, topotecan hydrochloride, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
48
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 23, 2026, 1:34 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus

NCT03258281
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Dyslipidemia Associated With Type II Diabetes Mellitus, Percutaneous Coronary Intervention
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 23, 2026, 1:34 AM EDT
Suspended Phase 3 Interventional

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Left Ventricular Dysfunction Trial

NCT06566183
View directory record Official record
Conditions
Coronary Artery Disease, Cognitive Impairment, Heart Failure
Interventions
Guideline-directed medical therapy (GDMT), Coronary artery bypass grafting (CABG), Percutaneous coronary intervention (PCI).
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 2 Interventional Results available

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

NCT02581930
View directory record Official record
Conditions
Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 1:34 AM EDT
Completed No phase listed Observational

Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy

NCT02724319
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
SpartanRX
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Not applicable Interventional

Physical Activity Telehealth Intervention After Percutaneous Coronary Procedures

NCT01673100
View directory record Official record
Conditions
Physical Activity
Interventions
Physical Activity Promotion Intervention
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 23, 2026, 1:34 AM EDT
Terminated Phase 2 Interventional Results available

A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention

NCT04848220
View directory record Official record
Conditions
Microvascular Obstruction
Interventions
Temanogrel, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Long Beach, California • Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 2Phase 3 Interventional

Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency

NCT00460096
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Kamada-API
Drug
Lead sponsor
Kamada, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Denver, Colorado • Gainesville, Florida • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2007 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Not applicable Interventional Results available

Sprinter Legend Balloon Catheter

NCT00961311
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Percutaneous Coronary Intervention, Sprinter Legend 1.25mm Balloon Catheter
Procedure · Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Oct 23, 2026, 1:34 AM EDT
Terminated Not applicable Interventional

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

NCT01268319
View directory record Official record
Conditions
Coronary Atherosclerosis, Myocardial Infarction, Coronary Plaque Embolization
Interventions
Embolic Protection Device (EPD), Intracoronary Spectroscopy and Ultrasonic Evaluation, Angioplasty and Stent Implant
Device
Lead sponsor
Infraredx
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
9
States / cities
Scottsdale, Arizona • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 1 Interventional

The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes

NCT01319331
View directory record Official record
Conditions
Diabetes, Type 1 Diabetes
Interventions
Alpha 1-Antitrypsin (AAT, Aralast NP)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 23, 2026, 1:34 AM EDT
Suspended No phase listed Observational

Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)

NCT00571272
View directory record Official record
Conditions
Liver Diseases, Alagille Syndrome, Alpha 1-Antitrypsin Deficiency
Interventions
Not listed
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
Up to 25 Years
Enrollment
1,675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2029
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 23, 2026, 1:34 AM EDT
Recruiting Not applicable Interventional

AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

NCT06959524
View directory record Official record
Conditions
Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries
Interventions
Drug Eluting Balloon, Drug eluting stent, Plain old balloon angioplasty
Device · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
48
States / cities
Scottsdale, Arizona • Jonesboro, Arkansas • La Jolla, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 2 Interventional Results available

Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting

NCT00357968
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel, Placebo for Prasugrel, Placebo for Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Jacksonville, Florida • Worcester, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 23, 2026, 1:34 AM EDT
Terminated Not applicable Interventional

Study Of Costs Realized After Percutaneous Coronary intervenTion Employing Same Day Discharge

NCT02207270
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Same day discharge, Overnight Stay
Behavioral
Lead sponsor
Trinity Health Michigan
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 23, 2026, 1:34 AM EDT
Completed No phase listed Observational

Groin Complications Post Percutaneous Coronary Intervention Using Either Manual Compression or PERCLOSE Device

NCT00842179
View directory record Official record
Conditions
Vascular Closure
Interventions
Not listed
Lead sponsor
Clinyx, LLC
Other
Eligibility
18 Years and older
Enrollment
2,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2009 · Synced Oct 23, 2026, 1:34 AM EDT